NASDAQ: TKNO · Life Sciences · 3 alerts · CIK 1850902
Share price
$7.77Close, Nov 16
Market cap
$489M
Shares outstanding
62.9MLatest SEC cover page
Sector
Life Sciences
Industry
In Vitro & In Vivo Diagnostic SubstancesSIC 2835
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Alpha Teknova, Inc. filings on SEC EDGAR ↗
Alpha Teknova reported a 22% increase in revenue for the third quarter of 2026 compared to the prior year, reaching $12.7 million. While the company continues to operate at a net loss, it improved its quarterly net loss from $4.3 million in 2025 to $3.5 million in 2026, driven by higher gross profits and controlled operating expenses.
Alpha Teknova reported record third quarter 2026 revenue of $12.7 million, a 22% increase year-over-year, driven by strong demand in Clinical Solutions and Lab Essentials. Based on the performance, the company raised its full-year 2026 revenue guidance to a range of $46 million to $48 million.
Term
Q3 2026
“We posted record revenue for the second consecutive quarter. Growth was driven by increased sales of products to life science tools and diagnostics, and to biopharma customers. Notably, there was an increase in purchases of our custom products by small and mid-sized biotech customers and their associated contract manufacturers, which we believe is an early indication of biotech funding improvements over the past four quarters.”
Stephen Gunstream, President and Chief Executive Officer
“We delivered excellent financial results in the third quarter 2026 compared to 2025, highlighted by 22% revenue growth and a significant improvement in Adjusted EBITDA and Free Cash Outflow. We are therefore raising our 2026 revenue guidance to $46-48 million and maintaining our expectations for full-year Free Cash Outflow of less than $8 million.”
Alpha Teknova, Inc. entered into an underwriting agreement for a public offering of 8,000,000 shares of common stock at $5.00 per share, generating $40 million in gross proceeds. The company granted underwriters a 30-day option to purchase up to 1,200,000 additional shares and intends to use the proceeds for general corporate purposes and potential debt repayment.